U.S. FDA allows 23andMe to sell test for 3 mutations of breast cancer gene

(Reuters) - The U.S. Food and Drug Administration on Tuesday allowed genetic testing company 23andMe to market directly to consumers its test that will help assess three mutations in a common type of breast cancer gene.